Evidence map›Paper›PMID 42253980›Full record

ArticleFrontiers in immunology2026

Interferon receptor gene dosage differentially regulates hypoxia-induced platelet activation and pulmonary hypertension in down syndrome.

Janelle N Posey, Mariah Jordan, Amanda Olsen-Dufour, Thi-Tina N Nguyen, Christine Farrell, Caitlin V Lewis, Jamie L Archambault, Christina Sul, Daniel Colon-Hidalgo, Eva S Nozik and 3 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Janelle N PoseySection of Neonatology, Department of Pediatrics, University of Colorado Anschutz, Aurora, CO, United States.
Mariah JordanSection of Neonatology, Department of Pediatrics, University of Colorado Anschutz, Aurora, CO, United States.
Amanda Olsen-DufourSchool of Medicine, University of Colorado Anschutz, Aurora, CO, United States.
Thi-Tina N NguyenSection of Pediatric Critical Care, Department of Pediatrics, University of Colorado Anschutz, Aurora, CO, United States.
Christine FarrellCardiovascular Pulmonary Research Laboratories, University of Colorado Anschutz, Aurora, CO, United States.
Caitlin V LewisSection of Pediatric Critical Care, Department of Pediatrics, University of Colorado Anschutz, Aurora, CO, United States.
Jamie L ArchambaultSection of Neonatology, Department of Pediatrics, University of Colorado Anschutz, Aurora, CO, United States.
Christina SulSection of Pediatric Critical Care, Department of Pediatrics, University of Colorado Anschutz, Aurora, CO, United States.
Daniel Colon-HidalgoCardiovascular Pulmonary Research Laboratories, University of Colorado Anschutz, Aurora, CO, United States.
Eva S NozikSection of Pediatric Critical Care, Department of Pediatrics, University of Colorado Anschutz, Aurora, CO, United States.
Joaquin M EspinosaLinda Crnic Institute for Down Syndrome, University of Colorado Anschutz, Aurora CO, United States.
Kelly D SullivanDepartment of Pharmacology, University of Colorado Anschutz, Aurora, CO, United States.
Cassidy DelaneySection of Neonatology, Department of Pediatrics, University of Colorado Anschutz, Aurora, CO, United States.

Funding

The INCLUDE Project Down Syndrome Biorepository (DS-Biorepository)U24AG092191 · NIA · UNIVERSITY OF COLORADO DENVER · PI Joaquin M. Espinosa, Matthew D Galbraith · 2024 to 2026
$15.8M
Trisomy 21 Model AtlasR24OD035579 · OD · UNIVERSITY OF COLORADO DENVER · PI Joaquin M. Espinosa, Matthew D Galbraith · 2023 to 2026
$3.0M
NIA NIH HHS U24 AG092191NIH HHS R24 OD035579
6 · The paper itself

Abstract

Trisomy 21 (T21) results in Down syndrome (DS), a condition associated with a high prevalence of pulmonary complications. Pulmonary hypertension (PH) is a significant comorbidity in individuals with T21. Inflammation is a well-established driver of PH, and growing evidence implicates platelets as active contributors to inflammatory-mediated pulmonary vascular disease and PH. In T21, increased interferon (IFN) signaling resulting from an additional IFN receptor gene locus contributes to immune dysregulation, and interactions between platelet activation and IFN signaling may promote thromboinflammatory pathways associated with vascular disease. To determine whether platelet activation is altered in T21, we first measured platelet activation by flow cytometry in individuals with T21 and age-matched controls. We then utilized the Dp16 mouse model of down syndrome to investigate IFN-dependent mechanisms. WT, Dp16, and Dp162xIfnrs mice 7-9 weeks of age were exposed to 10% hypobaric hypoxia for 3 or 21 days or remained at Denver altitude. Platelet activation was measured by flow cytometry. Lungs were collected to measure PF4 by ELISA and lung platelets by IHC. Vascular remodeling was measured by IHC staining of muscularized small vessels. PH was measured by RSVP and RV hypertrophy (RVH). Baseline and agonist-induced platelet activation were increased in individuals with T21, as evidenced by elevated platelet P-selectin expression and activated αIIbβ3. To investigate the immunoregulatory mechanisms underlying T21-associated PH, we utilized the Dp16 mouse model of Down syndrome in a chronic hypoxia model of PH. Consistent with our human findings, baseline, agonist-induced, and hypoxia-induced P-selectin and αIIbβ3 activation were elevated in Dp16 mice compared with wild-type (WT). Circulating PF4 and soluble GPVI were elevated at baseline and PF4 was further increased in hypoxic Dp16 mice. Lung PF4 levels were also increased at baseline and further elevated with hypoxia in Dp16 mice, despite comparable numbers of lung platelets. Dp16 mice demonstrated increased baseline pulmonary vascular remodeling, right ventricular systolic pressure (RVSP), and right ventricular hypertrophy (RVH) with both RVSP and RVH being further exacerbated in hypoxic Dp16 mice. Normalization of

Indexed as

Down SyndromeHypertension, PulmonaryHypoxiaPlatelet ActivationReceptors, InterferonAdultAnimalsBlood PlateletsChildDisease Models, AnimalFemaleHumansLungMaleMiceVascular RemodelingReceptors, Interferonhypoxiainterferonplateletpulmonary hypertensionthromboinflammationtrisomy 21vascular injury

Identifiers

PMID42253980
PMCPMC13236561

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.